Science of Enzymes

Alcresta Therapeutics is leveraging its proprietary research platform to discover and develop a new generation of enzyme-based products to help meet the needs of people living with gastrointestinal and rare diseases. 

Alcresta Therapeutics’ proprietary enzyme-based platform is initially being used to support people with compromised pancreatic output or malabsorption of crucial nutrients. Compromised pancreatic output is a condition that limits a person’s ability to produce digestive enzymes, which are critical to optimal nutrition, growth, development, and function. Changes in gastric, duodenal, liver, and pancreatic physiology can also dramatically impact malabsorption of critical nutrients, in particular fat absorption. 

These complex medical challenges can be a result of a variety of medical conditions that can affect pancreatic or digestive function, including cystic fibrosis (CF), digestive cancers (including pancreatic, gastric, and liver), and gastrointestinal diseases, chronic pancreatitis (CP), patients in the ICU, as well as during early development and aging. 

More than 90% of people with CF have a compromised pancreas and need enzyme-based products to properly digest and absorb vitamins and nutrients.1

To meet this need, Alcresta Therapeutics is leveraging its proprietary research platform to discover and develop a new generation of enzyme-based products. The company’s broad range of point-of-care products are designed to safely and easily improve digestion and absorption of important nutrients that are key to enhanced development and nutritional status.

Alcresta Therapeutics is creating a new class of tailored, enzyme-based, point-of-care products that can be used in conjunction with current standards of nutritional care. Maximizing nutrient and caloric absorption are key goals for managing the way nutritional aspects of growth, aging and disease are handled. 

Alcresta Therapeutics’ proprietary enzyme-based platform is initially being developed to support people with compromised pancreatic output or malabsorption of fats. 

1. Borowitz D et al. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr 2009;155(6):S73-S93.